Systemic RNAi delivery to the muscles of ROSA26 mice reduces lacZ expression

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wei, Jessica ^a   Chamberlain, Joel R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; BACTERIAL ENZYME; BETA GALACTOSIDASE; MICRORNA; SHORT HAIRPIN RNA; GT(ROSA)26SOR NON-CODING RNA, MOUSE; SMALL INTERFERING RNA; UNTRANSLATED RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; ENZYME ACTIVITY; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE SILENCING; HEART MUSCLE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INVERTED REPEAT; LACZ GENE; LIVER; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; ROSA26 MOUSE STRAIN; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; LACTOSE OPERON; METABOLISM; MUSCULAR DISEASES; NORTHERN BLOTTING; PROCEDURES; RNA INTERFERENCE; SKELETAL MUSCLE;

ANIMALS; BETA-GALACTOSIDASE; BLOTTING, NORTHERN; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; LAC OPERON; MICE; MUSCLE, STRIATED; MUSCULAR DISEASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, UNTRANSLATED;

EID: 84929056264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102053     Document Type: Article

References (48)

1. Sharp PA (1999) RNAi and double-strand RNA. Genes & Development 13: 139-141.
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
3. Zamore PD, Tuschl T, Sharp PA, Bartel DP (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33.
4. Lee Y, Kim M, Han J, Yeom KH, Lee S, et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. Embo J 23: 4051-4060. (Pubitemid 39472426)
5. Zeng Y, Cullen BR (2002) RNA interference in human cells is restricted to the cytoplasm. Rna 8: 855-860. (Pubitemid 34787682)
6. Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366. (Pubitemid 32151243)
7. Lee Y, Ahn C, Han J, Choi H, Kim J, et al. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419. (Pubitemid 37187272)
8. Hammond SM, Bernstein E, Beach D, Hannon GJ (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-296. (Pubitemid 30163547)
9. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 20: 6877-6888. (Pubitemid 33134217)
10. Lambeth LS, Smith CA (2013) Short Hairpin RNA-Mediated Gene Silencing. In: Taxman DJ, editor. siRNA Design: Humana Press. pp. 205-232.
11. Wang H, Yang B, Qiu L, Yang C, Kramer J, et al. (2014) Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Molec Genet 23: 668-681.
12. Yang W-Q, Zhang Y (2012) RNAi-mediated gene silencing in cancer therapy. Expert Opinion on Biological Therapy 12: 1495-1504.
13. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
14. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, et al. (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68.
15. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16: 948-958. (Pubitemid 34408544)
16. Paul CP, Good PD, Winer I, Engelke DR (2002) Effective expression of small interfering RNA in human cells. Nat Biotechnol 20: 505-508. (Pubitemid 34495939)
17. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541. (Pubitemid 44050158)
18. Grimm D, Kay MA (2007) Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 117: 3633-3641. (Pubitemid 350224069)
19. Grimm D, Wang L, Lee JS, Schurmann N, Gu S, et al. (2010) Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 120: 3106-3119.
20. Vickers TA, Lima WF, Nichols JG, Crooke ST (2007) Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res 35: 6598-6610. (Pubitemid 350111625)
21. Borel F, Kay MA, Mueller C (2014) Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther 4:692-701.
22. Koornneef A, Maczuga P, van Logtenstein R, Borel F, Blits B, et al. (2011) Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. Mol Ther 19: 731-740.
23. Wallace LM, Liu J, Domire JS, Garwick-Coppens SE, Guckes SM, et al. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther 20: 1417-1423.
24. Wallace LM, Garwick-Coppens SE, Tupler R, Harper SQ RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1). Mol Ther 19: 2048-2054.
25. Bortolanza S, Nonis A, Sanvito F, Maciotta S, Sitia G, et al. (2011) AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol Ther 19: 2055-2064.
26. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12: 787-789. (Pubitemid 44050067)
27. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, et al. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10: 828-834. (Pubitemid 39070856)
28. Odom GL, Gregorevic P, Allen JM, Chamberlain JS (2011) Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther 19: 36-45.
29. Duan D, Sharma P, Yang J, Yue Y, Dudus L, et al. (1998) Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72: 8568-8577. (Pubitemid 28471794)
30. Schultz BR, Chamberlain JS (2008) Recombinant adeno-associated virus transduction and integration. Mol Ther 16: 1189-1199. (Pubitemid 351866049)
31. Zambrowicz BP, Imamoto A, Fiering S, Herzenberg LA, Kerr WG, et al. (1997) Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci (USA) 94: 3789-3794. (Pubitemid 27180451)
32. Harper SQ, Davidson BL (2005) Plasmid-based RNA interference: construction of small-hairpin RNA expression vectors. Methods Mol Biol 309: 219-235.
33. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, et al. (1997) Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 71: 5932-5941. (Pubitemid 27304930)
34. Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, et al. (2004) Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 10: 671-678. (Pubitemid 39272856)
35. Bortolanza S, Nonis A, Sanvito F, Maciotta S, Sitia G, et al. (2011) AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Molecular Therapy 19: 2055-2064.
36. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, et al. (2008) Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci (USA) 105: 2111-2116. (Pubitemid 351439473)
37. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, et al. (2009) Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 105: 585-594.
38. Gregorevic P, Meznarich NA, Blankinship MJ, Crawford RW, Chamberlain JS (2008) Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. Muscle Nerve 37: 104-106.
39. Odom GL, Gregorevic P, Chamberlain JS (2007) Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta 1772: 243-262. (Pubitemid 46123917)
40. Xiao X, Li J, Samulski RJ (1996) Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. Journal of Virology 70: 8098-8108. (Pubitemid 26339120)
41. Boudreau RL, Martins I, Davidson BL (2009) Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17: 169-175.
42. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 105: 5868-5873. (Pubitemid 351758464)
43. Giering JC, Grimm D, Storm TA, Kay MA (2008) Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16: 1630-1636.
44. Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, et al. (2007) Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 15: 320-329. (Pubitemid 46111882)
45. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, et al. (2004) Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388. (Pubitemid 38715936)
46. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99: 11854-11859. (Pubitemid 34994488)
47. Arnett A, Ramos JN, Chamberlain JS (2012) Viral Gene Therapy in Skeletal Muscle. In: Hill JJ, Olson EN, editors. Muscle: Fundamental Biology and Mechanisms of Disease. Amsterdam: Elsevier. pp. 1045-1052.
48. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, et al. (2010) Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28: 79-82.